TIDMAPH

RNS Number : 6343V

Alliance Pharma PLC

15 April 2021

 
           15 April 2021

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Directorate Change

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that Nigel Clifford, a Non-Executive Director, will leave the Group on 30 April 2021 after serving for six years.

Nigel was appointed to Alliance's Board as a Non-Executive Director on 26 January 2015, since which time he has made a significant contribution to both the development and governance of the Group. Nigel's formal notice period has been waived by the Board owing to his other business commitments.

The recruitment process to appoint a replacement Non-Executive Director is underway and a further announcement will be made in due course.

David Cook, Alliance Pharma's Chairman, said: "On behalf of the Board, I extend our sincere thanks to Nigel for his wise counsel to the Board and its Committees as a Non-Executive Director during the past six years. During that time, Nigel has added significant value to Alliance, particularly in connection with the Group's international expansion, and we wish him well in his future endeavours."

For further information:

 
 Alliance Pharma plc                          + 44 (0)1249 466966 
 Peter Butterfield, Chief Executive 
  Officer 
 Andrew Franklin, Chief Financial Officer 
 www.alliancepharma.co.uk 
 Buchanan                                    + 44 (0)20 7466 5000 
 Mark Court / Sophie Wills / Hannah 
  Ratcliff 
 
 Numis Securities Limited                    + 44 (0)20 7260 1000 
 Nominated Adviser: Freddie Barnfield 
  / Oliver Steele 
 Corporate Broking: James Black 
 
 
 Investec Bank plc                  + 44 (0) 20 7597 5970 
 Corporate Finance: Daniel Adams 
 Corporate Broking: Patrick Robb

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We hold the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused primarily on our Consumer healthcare brands, many of which have significant international or multi-territory reach. Our Prescription Medicines are generally sold in a more limited number of local markets, and most require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website : www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOADZGMDFKGGMZM

(END) Dow Jones Newswires

April 15, 2021 09:45 ET (13:45 GMT)

Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Alliance Pharma Charts.
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Alliance Pharma Charts.